No data available
All Partners have extensive experience, including senior executive positions in large pharmaceutical and entrepreneurial biotechnology companies. Their collective experience extends across business development and licensing, drug discovery and development, marketing, intellectual property management, venture capital and investment banking.. . Our client list ranges from small European start-ups through established US biotechs to large Japanese pharmaceutical companies. Kagulex Consulting provides a range of business and product development services including:. . -Global Product and Patent Licensing and Corporate Partnering. -Intellectual Property Strategy and Management. -Merger and Acquisition Advice and Due Diligence. -Pre-clinical Planning and Implementation. -Clinical and Regulatory Strategy Development and Implementation. -Strategic Business Plan Development. -Product and Technology Assessment. -Venture Facilitation
As the leading kidney research charity in the UK, nothing is going to stop us in our urgent mission to end kidney disease. We’re here to be heard, to make a difference, to change the future. This is a disease that ruins and destroys lives. It must be stopped.
Over the past 60 years, our research has made an impact. But kidney failure is rising, as are the factors contributing to it, such as diabetes and obesity.
Today, we are more essential than ever.
Kidney disease affects three million people in the UK, treatments can be gruelling and currently there is no cure. Only research will end this and nobody can do it but us, by offering kidney patients and their families hope for the future. We’re taking it on. But we can’t do it without you.
Over the past 60 years, our research has made an impact. But kidney failure is rising, as are the factors contributing to it, such as diabetes and obesity.
Today, we are more essential than ever.
Kidney disease affects three million people in the UK, treatments can be gruelling and currently there is no cure. Only research will end this and nobody can do it but us, by offering kidney patients and their families hope for the future. We’re taking it on. But we can’t do it without you.
King's Business is responsible for driving innovation at King's College London. Through the development of new opportunities and partnerships we optimise the impact of research and create value for the College in its externally-facing activities. This includes securing partnerships with business and other sectors through diverse mechanisms such as patenting and licensing, the creation of spin-out companies, collaborative and contract research, consultancy and staff secondments to and from industry.
KISS - the multiplier agency.
An award-winning B2B marketing agency where expertise meets an unwavering desire for exceptional results. If you’re ambitious about multiplying the impact of your marketing performance, we are the agency to help your grow your business.
Fuelled by a team of experts across strategy, creativity, technology and performance, we will amplify your marketing performance and grow your business through our theory of multiplication: Creativity x Technology x Data.
We harness the power of creativity to ensure you stand out in the marketplace, enabling this with the latest technology. Everything we do is informed by data to deliver your message through the right channels, to the right audiences, at the right time to deliver maximum impact.
From concept to completion, our projects multiply results.
Growth is good. Multiplying is better.
An award-winning B2B marketing agency where expertise meets an unwavering desire for exceptional results. If you’re ambitious about multiplying the impact of your marketing performance, we are the agency to help your grow your business.
Fuelled by a team of experts across strategy, creativity, technology and performance, we will amplify your marketing performance and grow your business through our theory of multiplication: Creativity x Technology x Data.
We harness the power of creativity to ensure you stand out in the marketplace, enabling this with the latest technology. Everything we do is informed by data to deliver your message through the right channels, to the right audiences, at the right time to deliver maximum impact.
From concept to completion, our projects multiply results.
Growth is good. Multiplying is better.
Korecyte Bio is a preclinical biotech startup incorporated in 2023 in NL (Korecyte Bio BV) and in the UK (Korecyte Innovations Ltd.) The company has developed a genetic switching platform that can be fused to any CAR-based cell therapeutic, like CAR-T, as a stringent tumour-selective switch that can render the cells much safer and more effective in attacking a solid tumour.
No data available
Kymab is a biopharmaceutical company using a proprietary transgenic antibody platform, Kymouse, to discover and develop fully human monoclonal antibody drugs. The technology used to design the Kymouse strains originated from the Wellcome Trust Sanger Institute in Cambridge, UK. Kymouse™ has been designed to maximise the diversity of human antibodies produced in response to immunisation. Selecting from a broad diversity of fully human antibodies assures the highest probability of finding that rare drug candidate with best-in-class characteristics.
No data available
Latham & Watkins are a global international law firm offering life sciences and healthcare industry leaders deep sector knowledge, legal expertise, and commercial and government insights. Latham’s cross-disciplinary healthcare and life sciences team delivers insightful, practical guidance and sophisticated representation to a full spectrum of companies across the globe, on every type of transaction or dispute a company may face. Many of us hold advanced scientific degrees and have served in senior positions as government regulators, C-Suite executives in leading healthcare and life sciences companies, as well as serving as primary outside counsel for key industry associations.
Watch our Member Showcase Video https://bit.ly/3rsZDkp
Watch our Member Showcase Video https://bit.ly/3rsZDkp